AstraZeneca plc (AZN) Upgraded to Buy at Bryan, Garnier & Co

Bryan, Garnier & Co upgraded shares of AstraZeneca plc (LON:AZN) to a buy rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have GBX 5,380 ($69.48) target price on the biopharmaceutical company’s stock, up from their previous target price of GBX 4,700 ($60.70).

Other equities analysts have also issued reports about the stock. Berenberg Bank upped their target price on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the stock a buy rating in a research report on Wednesday, May 17th. Liberum Capital reiterated a buy rating and set a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a research report on Tuesday, May 23rd. UBS AG set a GBX 5,150 ($66.51) target price on shares of AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. Finally, Credit Suisse Group reduced their target price on shares of AstraZeneca plc from GBX 5,000 ($64.57) to GBX 4,700 ($60.70) and set a neutral rating on the stock in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. AstraZeneca plc has a consensus rating of Hold and an average price target of GBX 5,022.91 ($64.87).

AstraZeneca plc (AZN) opened at 4806.00 on Monday. The firm has a 50-day moving average of GBX 4,566.78 and a 200 day moving average of GBX 4,881.73. The firm’s market cap is GBX 60.84 billion. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

TRADEMARK VIOLATION WARNING: This piece was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/15/astrazeneca-plc-azn-upgraded-to-buy-at-bryan-garnier-co.html.

The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply